RE:Trading Update from the DumpsterAnd let me guess ... none of our resident trolls have anything positive to say about ...
1. elimination of T3 and T4 in place of molar extraction - to free up lab time for other things.
2. addition of molar to reduce trial risk (dosing determination).
3. moved up P2 timeline from November to October.
4. moved up P2 timeline from October to September.
5. added 3 more opportunities on the IBD side - making it 5 candidates now ? What does that mean ? Specific opportunities for different indications ? Interesting yet unknown.
5. keeping cash burn to $1.6 MM per month while growing our funnel and moving it forward - that's what you want when 346 negotiations come around.
In a drug development company, these are the things that matter - but I'm sure our trolls haven't the foggiest. Miss their humor. : )
Always mind the risk - that's on you !!!
Now ... what are they doing with the extra lab time this summer (since T3 and T4 were cancelled in favor of molar extraction) ? Hmmmmmm